Zhao P, Li L, Zhou S, et al. - Since CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) has never been studied on a large scale in China, researchers undertook this inquiry to demonstrate that CD5+ DLBCL occurs at a low frequency (9.2%). Tumours with a higher prevalence of BCL-2 and p53 overexpression were present in patients with CD5+ DLBCL vs CD5− DLBCL. Inferior progression-free survival (PFS) and overall survival (OS) were experienced by patients with CD5+ DLBCL vs those with CD5− DLBCL. Significantly better PFS and OS were observed in relation to treatment with rituximab vs treatment without rituximab in patients with CD5+ DLBCL. However, similar PFS and OS were experienced by patients treated with RCHOP vs the group treated with intensive therapy. The worst PFS and OS were experienced by those with p53 and CD5 co-expression. Findings revealed the link of CD5+ DLBCL with unfavorable clinicopathologic variables and inferior survival. A high frequency of p53 overexpression was noted in CD5+ DLBCL. Also, the negative influence of p53 overexpression in DLBCL was augmented by CD5.